Chen et al. verified that prolonged sorafenib treatment induced increases in levels of CXCR4 and its ligand SDF-1α in HCC, resulting in enhancement of cancer cell survival and promotion of metastatic phenotypes in HCC [21, 22]. This evidence concerns the gene CXCL12 and hepatocellular carcinoma.